November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Myeloma Paper of the Day, November 9th, suggested by Robert Orlowski
Nov 9, 2024, 16:02

Myeloma Paper of the Day, November 9th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Study from Mohammed VI University Hospital in Morocco of 224 patients with monoclonal gammopathy finds higher than expected rate of myeloma vs. MGUS, possibly from healthcare access variations and demographic characteristics!”

Characterizing Monoclonal Gammopathies in an East Moroccan Population: University Hospital Findings

Authors: Oussama Grari, Kaoutar Benaissa, Nisma Douzi, Imad-Eddine Elkhamlichi, Amina Himri, Dounia Elmoujtahide, El-Houcine Sebbar, Mohammed Choukri.

Myeloma Paper of the Day, November 9th, suggested by Robert Orlowski

 

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.